BAXTER INTERNATIONAL INC

Baxter International Inc. is a global healthcare company that provides essential healthcare products, including acute and chronic dialysis therapies, sterile intravenous solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, advanced surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company was incorporated in Delaware in 1931 and generates revenue from four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. Baxter International's business strategy focuses on driving sustainable growth and innovation, expanding its portfolio geographically, improving operational efficiency, and allocating capital wisely. The company's website is [www.baxter.com], and its ticker symbol is BAX. Recently, Baxter International announced strategic actions, including a proposed spinoff of its Kidney Care business, the implementation of a new operating model, and the sale of its BioPharma Solutions business. The Kidney Care business generated $4.45 billion in net sales in 2022 and 2023, representing approximately 30% and 31% of the company's consolidated net sales, respectively. The proposed spinoff is subject to customary conditions, including regulatory approvals and stockholder approval. Baxter International also completed the acquisition of Hillrom Holdings, Inc. in December 2021 for $12.84 billion, including the assumption of Hillrom's outstanding debt obligations. Hillrom is a global medical technology leader that provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space. The Healthcare Systems and Technologies segment generated $3.01 billion and $2.94 billion in net sales in 2023 and 2022, respectively. Baxter International's business strategy includes a focus on innovation, market expansion, operational efficiency, and capital allocation. The company's innovation strategy includes organic and inorganic initiatives to accelerate sales growth through the introduction of new connected care and core therapies offerings. Market expansion includes expanding the portfolio geographically, broadening the portfolio through channel expansion, and increasing utilization of products and therapies through market development activities. Operational efficiency includes simplifying and streamlining operations, increasing efficiencies through automation and digitization, and delivering targeted cost synergies. Capital allocation strategies include debt repayments, active portfolio management, and returning capital to stockholders through dividends and share repurchases.